Adenocarcinoma Clinical Trials

943 recruitingLast updated: June 17, 2026

There are 943 actively recruiting adenocarcinoma clinical trials across 59 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Los Angeles, California, United States. Updated daily from ClinicalTrials.gov.


Adenocarcinoma Trials at a Glance

943 actively recruiting trials for adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 59 countries. The largest study group is Phase 2 with 415 trials, with the heaviest enrollment activity in Houston, New York, and Los Angeles. Lead sponsors running adenocarcinoma studies include Mayo Clinic, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

Browse adenocarcinoma trials by phase

Treatments under study

About Adenocarcinoma Clinical Trials

Looking for clinical trials for Adenocarcinoma? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 943 trials

Recruiting
Phase 1Phase 2

Study for AZD4360 in Participants With Advanced Solid Tumours

Gastric CancerGastroesophageal-junction CancerBiliary Tract Cancer+1 more
AstraZeneca117 enrolled18 locationsNCT06921928
Recruiting
Not Applicable

Family Communications After Genetic Testing

Stage IV Colorectal Cancer AJCC v8Stage I Colorectal Cancer AJCC v8Stage II Colorectal Cancer AJCC v8+12 more
Alliance for Clinical Trials in Oncology4,186 enrolled242 locationsNCT07143487
Recruiting
Phase 3

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled293 locationsNCT06764875
Recruiting
Not Applicable

Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)

Pancreatic CancerMetastatic Pancreatic CancerPancreatic Adenocarcinoma+1 more
Alpha Tau Medical LTD.15 enrolled2 locationsNCT05657743
Recruiting
Phase 2Phase 3

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal AdenocarcinomaPDAC
AbbVie900 enrolled11 locationsNCT07490301
Recruiting
Phase 2

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Locally Advanced Rectal AdenocarcinomaMicrosatellite Stable Rectal Carcinoma
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT06843434
Recruiting
Not Applicable

Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer

Pancreatic CancerPancreatic AdenocarcinomaUnresectable Pancreatic Cancer
Alpha Tau Medical LTD.15 enrolled1 locationNCT06026943
Recruiting
Phase 3

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Stage IVB Prostate Cancer AJCC v8Metastatic Prostate AdenocarcinomaMetastatic Castration-Resistant Prostate Carcinoma
Alliance for Clinical Trials in Oncology1,524 enrolled98 locationsNCT07200830
Recruiting
Not Applicable

Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

Pancreatic CancerMetastatic Pancreatic CancerPancreatic Adenocarcinoma
Alpha Tau Medical LTD.40 enrolled15 locationsNCT06698458
Recruiting
Phase 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Locally Advanced Cervical Adenocarcinoma+5 more
National Cancer Institute (NCI)336 enrolled266 locationsNCT07061977
Recruiting

Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy

Esophageal CarcinomaEsophageal AdenocarcinomaEsophagectomy+2 more
Sun Yat-sen University2,500 enrolled6 locationsNCT07309991
Recruiting
Phase 2

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

Squamous Cell Carcinoma of the BladderAdenocarcinoma of the BladderTesticular Germ Cell Tumors
National Cancer Institute (NCI)68 enrolled1 locationNCT06041503
Recruiting
Phase 2

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Recurrent Endometrial CarcinomaEndometrial AdenocarcinomaEndometrial Clear Cell Adenocarcinoma+6 more
National Cancer Institute (NCI)81 enrolled137 locationsNCT05112601
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled578 locationsNCT03866382
Recruiting
Phase 2

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell CarcinomaResectable Pancreatic CarcinomaResectable Pancreatic Adenocarcinoma+4 more
National Cancer Institute (NCI)152 enrolled454 locationsNCT04858334
Recruiting
Phase 2

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)G12D Mutated KRAS
Verastem, Inc.180 enrolled8 locationsNCT07644559
Recruiting
Phase 2

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma
AstraZeneca100 enrolled70 locationsNCT07069712
Recruiting
Phase 2Phase 3

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+13 more
National Cancer Institute (NCI)224 enrolled372 locationsNCT06203600
Recruiting
Phase 2

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

Prostate CancerProstate AdenocarcinomaHormone Sensitive Prostate Cancer
University of Miami34 enrolled1 locationNCT06392295
Recruiting
Phase 3

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.670 enrolled3 locationsNCT07621718